Ocular Therapeutix - OCUL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.80
  • Forecasted Upside: 115.38%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.80
▼ -0.19 (-2.38%)

This chart shows the closing price for OCUL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ocular Therapeutix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCUL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCUL

Analyst Price Target is $16.80
▲ +115.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $16.80, with a high forecast of $24.00 and a low forecast of $12.00. The average price target represents a 115.38% upside from the last price of $7.80.

This chart shows the closing price for OCUL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Ocular Therapeutix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$24.00N/A
2/26/2024Piper SandlerBoost TargetOverweight ➝ Overweight$10.00 ➝ $15.00Low
2/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
2/9/2024Bank of AmericaInitiated CoverageBuy$15.00Low
10/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
9/14/2023Robert W. BairdReiterated RatingOutperform ➝ Outperform$18.00Low
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
6/13/2023Robert W. BairdBoost Target$10.00 ➝ $12.00Low
6/13/2023HC WainwrightBoost Target$10.00 ➝ $12.00Low
5/9/2023HC WainwrightLower Target$11.00 ➝ $10.00Low
5/9/2023JMP SecuritiesBoost Target$11.00 ➝ $12.00Low
4/20/2023Robert W. BairdInitiated CoverageOutperform$18.00Low
3/7/2023JMP SecuritiesLower TargetMarket Outperform$12.00 ➝ $11.00Low
3/7/2023HC WainwrightReiterated RatingBuy$11.00Low
2/13/2023JMP SecuritiesReiterated RatingMarket Outperform$12.00Low
2/13/2023HC WainwrightBoost TargetBuy$9.00 ➝ $11.00Low
1/9/2023JMP SecuritiesLower TargetMarket Outperform$25.00 ➝ $12.00Low
11/8/2022HC WainwrightLower TargetBuy$10.00 ➝ $9.00N/A
11/8/2022Raymond JamesLower TargetStrong-Buy$29.00 ➝ $14.00Low
8/9/2022JMP SecuritiesBoost TargetMarket Outperform$20.00 ➝ $25.00Low
7/6/2022JMP SecuritiesReiterated RatingBuy$20.00N/A
5/27/2022Piper SandlerLower Target$16.00 ➝ $10.00Low
5/10/2022HC WainwrightLower Target$14.00 ➝ $10.00High
5/10/2022Piper SandlerLower Target$20.00 ➝ $16.00High
3/1/2022JMP SecuritiesLower TargetMarket Outperform$30.00 ➝ $22.00Medium
12/7/2021HC WainwrightReiterated RatingBuy$14.00High
11/9/2021JMP SecuritiesBoost TargetOutperform$27.00 ➝ $30.00High
10/25/2021HC WainwrightReiterated RatingBuy$18.00 ➝ $14.00High
10/24/2021Piper SandlerLower TargetOverweight$27.00 ➝ $20.00High
10/18/2021Raymond JamesBoost TargetStrong-Buy$25.00 ➝ $29.00Low
10/12/2021HC WainwrightBoost TargetBuy$17.00 ➝ $18.00High
10/8/2021JMP SecuritiesReiterated RatingBuy$33.00Low
9/24/2021JMP SecuritiesReiterated RatingBuy$33.00Medium
9/9/2021JMP SecuritiesBoost TargetMarket Outperform$33.00High
8/20/2021JMP SecuritiesReiterated RatingBuy$30.00High
8/10/2021HC WainwrightUpgradeNeutral ➝ Buy$17.00High
7/23/2021Piper SandlerReiterated RatingBuy$28.00High
12/30/2020JMP SecuritiesBoost Target$20.00 ➝ $30.00N/A
12/28/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
12/21/2020Piper SandlerBoost Target$16.00 ➝ $28.00Low
12/17/2020Berenberg BankInitiated CoverageBuy$27.00Medium
11/13/2020Raymond JamesBoost TargetStrong-Buy$15.00 ➝ $25.00High
11/6/2020HC WainwrightBoost TargetBuy$13.00 ➝ $14.00High
9/30/2020HC WainwrightReiterated RatingBuy$13.00High
8/10/2020HC WainwrightBoost TargetBuy$10.00 ➝ $13.00High
7/22/2020Piper SandlerBoost TargetOverweight$11.00 ➝ $14.00Low
4/29/2020HC WainwrightReiterated RatingPositive ➝ Buy$8.00 ➝ $10.00High
3/17/2020Jefferies Financial GroupInitiated CoverageBuy$8.00High
3/5/2020Piper SandlerReiterated RatingOverweight$7.00 ➝ $11.00High
3/4/2020HC WainwrightReiterated RatingBuy$8.00High
3/3/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
2/10/2020Piper SandlerBoost Target$5.50 ➝ $7.00Low
2/10/2020HC WainwrightReiterated RatingBuy ➝ Positive$6.00 ➝ $8.00Medium
11/15/2019HC WainwrightReiterated RatingBuy$9.00 ➝ $6.00High
11/12/2019Piper Sandler CompaniesLower TargetOverweight$8.00 ➝ $5.00High
10/18/2019HC WainwrightReiterated RatingBuy$9.00Low
9/25/2019HC WainwrightReiterated RatingBuy$9.00High
7/26/2019Piper Sandler CompaniesSet TargetBuy$8.00N/A
7/2/2019Piper Sandler CompaniesSet TargetBuy$8.00Low
7/2/2019HC WainwrightSet TargetBuy$9.00Low
6/24/2019HC WainwrightReiterated RatingBuy$9.00High
6/21/2019JMP SecuritiesSet TargetBuy$9.00Low
5/21/2019HC WainwrightLower TargetBuy$12.00 ➝ $9.00High
5/21/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$11.00 ➝ $5.00High
5/21/2019CowenDowngradeOutperform ➝ Market Perform$13.00 ➝ $3.00High
5/20/2019Piper Sandler CompaniesLower TargetOverweight ➝ Market Perform$8.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/18/2023
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/17/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 12 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/16/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 7 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Ocular Therapeutix logo
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $7.80
Low: $7.58
High: $7.96

50 Day Range

MA: $8.63
Low: $5.00
High: $10.93

52 Week Range

Now: $7.80
Low: $2.00
High: $11.31

Volume

1,494,201 shs

Average Volume

1,986,333 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocular Therapeutix?

The following Wall Street sell-side analysts have issued stock ratings on Ocular Therapeutix in the last year: Bank of America Co., HC Wainwright, JMP Securities, Piper Sandler, Robert W. Baird, and StockNews.com.
View the latest analyst ratings for OCUL.

What is the current price target for Ocular Therapeutix?

5 Wall Street analysts have set twelve-month price targets for Ocular Therapeutix in the last year. Their average twelve-month price target is $16.80, suggesting a possible upside of 115.4%. JMP Securities has the highest price target set, predicting OCUL will reach $24.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Ocular Therapeutix in the next year.
View the latest price targets for OCUL.

What is the current consensus analyst rating for Ocular Therapeutix?

Ocular Therapeutix currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUL will outperform the market and that investors should add to their positions of Ocular Therapeutix.
View the latest ratings for OCUL.

What other companies compete with Ocular Therapeutix?

How do I contact Ocular Therapeutix's investor relations team?

Ocular Therapeutix's physical mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company's listed phone number is (781) 357-4000 and its investor relations email address is [email protected]. The official website for Ocular Therapeutix is www.ocutx.com. Learn More about contacing Ocular Therapeutix investor relations.